

INVESTIGATOR INITIATED RESEARCH ASSESSMENT

Date:	
IISA Committee	

General Research Information (please complete)					
Protocol Title:	General Research Information (picase complete)				
Principal	Name:				
Investigator:	Title:				
	Email:				
	Phone:				
	Fax:				
Other	Name:				
Investigators:	Title:				
	Email:				
	Office:				
	Phone:				
	Fax:				
Study	Name:				
Coordinator:	Title:				
Contact information	Email:				
IIIIOIIIIatioii	Phone:				
	Fax:				
Project No. (if					
applicable) Type of Study:	Drug Safety/Efficacy Phase I Phase II				
Type of Study:	□ Drug □ Safety/Efficacy □ Phase I □ Phase II □ Device □ Registry □ Phase III □ Phase IV				
	Specimen Behavioral Observational				
	Treatment Phenomenological New Indication				
Trial Costs					
Project					
Financial	1. Total project budget:				
Support:					
	2. Source of support (drug or device manufacturer; other company; agency or foundation;				
	3. Chair or departmental administrator signature:				
	Signature Date:				

Location of	☐ Drexel Med ☐ Tower Health ☐ SCHC						
study:	Inpatient Outpatie						
	Additional Study Locations:						
Number of							
Subjects to be							
Enrolled:							
Additional							
comments							
	Sponsor 1	Responsib	ilities (p	lease cor	nplete)		
Is the investigator	required to obtain an IND or				1 222)		
IDE to conduct this	s research?	☐ Yes	□ No				
		Name of Sponsor:					
		IND No.	IND No.				
		IDE No.					
		501 (k) No.					_
Does the study inve	olva off label usa?	Yes	□ No				
Does the study hiv	orve orr-raber use:						
	olve administration of drug in other drugs that is not	☐ Yes	□ No				
What aspect of the	study is considered a						
deviation from SO	C?						
Radiation Exposure & Biosafety (please complete)							
Does the protocol i	involve exposure to radiation?	SOC		Yes	□ No		
		Research Pro	ocedure	☐ Yes	☐ No		
Should the protoco	l be submitted for Radiation	Yes	□ No				
Safety Committee							
	involve use of biohazards or	☐ Yes	No				
recombinant mater	181 /						
	l be submitted for Biosafety	☐ Yes	□ No				
Committee review	?						
L		1					

Legal (do not complete)					
Is there a contract between Institution and any third parties regarding this research study?	☐ Yes ☐ No				
If so, does the third party provide any indemnification? Describe.	☐ Yes ☐ No				
If so, is the Institution required to provide any indemnification? Describe.	☐ Yes ☐ No				
Comments:					
	t / Intellectual Property (do not complete)				
Conflict of Interest Assessment:	Reviewed by:				
Was the conflict of interest documentation completed?	☐ Yes ☐ No Comment:				
Is there any potential intellectual property?	☐ Yes ☐ No Comment:				
Risk Management (do not complete)					
Risk Management Assessment:	Reviewed by:				
Is there any experimental procedures? Include in Clinical Trials Insurance Policy:	Yes No Yes No Comment:				

Clinical Research Support (do not complete)						
Should the investigator invinvestigators?		Yes	□ No	• /		
Does the investigator need support staff to manage the		☐ Yes	No			
If yes, what type of suppor basis? Also, on a part-tim						
	IISA	Committ	tee Recomn	nendation		
Approve Disapprove Surface Disapprove Risk management Review to be done by WIRB						
		Addition	nal Comme	ents		
Approvals						
Signature of the approvers` signifies agreement that the IISA Committee approves this protocol for signature by the vice dean for research.						
Name	Author's Title	9	Signature	Date		
Name	Title	9	Signature	Date		